S1 Table. Patients characteristics according to CIN and FN

Characteristic	Without CIN (n=129)	With CIN (n=71)	p-value	Without FN (n=170)	With FN (n=30)	p-value
Age (yr)	63 (16-88)	59 (30-86)	0.574	62 (16-88)	59 (34-86)	0.411
Age ≥ 65 yr	60 (46.5)	29 (40.8)	0.440	78 (45.9)	11 (36.7)	0.349
Male sex	84 (65.1)	34 (47.9)	0.024	106 (62.4)	12 (40.0)	0.022
ECOG						
0-1	113 (87.6)	52 (73.2)	0.007	148 (87.1)	17 (56.7)	< 0.001
≥2	15 (11.6)	19 (26.8)		21 (12.4)	13 (43.3)	
Unknown	1 (0.8)			1 (0.5)		
IPI risk group						
Low (0-2)	84 (65.2)	28 (39.4)	< 0.001	106 (62.4)	6 (20.0)	< 0.001
High (3-5)	44 (34.0)	43 (60.6)		63 (37.1)	24 (80.0)	
Unknown	1 (0.8)			1 (0.5)		
Ann Arbor stage						
< 3	63 (48.8)	15 (21.1)	< 0.001	77 (45.3)	1 (3.3)	< 0.001
≥ 3	66 (21.2)	56 (78.9)		93 (54.7)	29 (96.7)	
B Symptom	27 (22.0)	25 (35.2)	0.003	39 (22.9)	13 (43.3)	0.010
Bulky disease	18 (14.1)	8 (11.3)	0.575	23 (13.5)	3 (10.0)	0.772
Extranodal involvement						
None	55 (42.6)	19 (26.8)	0.020	70 (41.2)	4 (13.3)	0.003
Single	41 (31.8)	21 (29.6)		53 (31.2)	9 (30.0)	
≥2	33 (25.6)	31 (43.7)		47 (27.6)	17 (56.7)	
LDH elevation	81 (62.8)	52 (73.2)	0.115	106 (62.4)	27 (90.0)	0.003
B2MG	2.30 (0.85-15.27)	2.75 (1.16-16.19)	0.024	2.34 (0.85-15.27)	3.74 (1.35-16.19)	0.002
Albumin	4.2 (2.5-5.2)	3.8 (2.0-4.8)	< 0.001	4.1 (2.5-5.2)	3.36 (2.0-4.5)	< 0.001
Albumin < 3.3	8 (6.2)	21 (29.6)	< 0.001	15 (8.8)	14 (46.7)	< 0.001
Hans criteria for DLBCL						
GCB	34 (26.4)	19 (26.8)	0.806	44 (25.9)	9 (30.0)	0.733
ABC	79 (61.2)	48 (67.6)		108 (63.5)	19 (63.3)	
Unknown	16 (12.4)	4 (5.6)		18 (10.6)	2 (6.7)	
Double express						
None	5 (3.8)	2 (2.8)	0.681	6 (3.5)	1 (3.3)	> 0.99
Double	18 (14.0)	13 (18.3)		25 (14.7)	6 (20.0)	
Unknown	106 (82.2)	56 (78.9)		139 (81.8)	23 (76.7)	
Bone marrow involvement	13 (10.1)	21 (29.6)	< 0.001	21 (12.4)	13 (43.3)	< 0.001
Median cellularity (%)	40	35	0.330	40	37.5	0.030
Chromosome						
Normal	105 (81.4)	50 (70.4)	0.320	140 (82.4)	15 (50.0)	0.002
Abnormal	20 (15.5)	14 (19.7)		24 (14.1)	10 (33.3)	
Unknown	4 (3.1)	7 (9.9)		6 (3.5)	5 (16.7)	
Initial chemotherapy dose						
Standard	77 (59.7)	48 (67.6)	0.269	106 (62.4)	19 (63.3)	0.919
Reduced	52 (40.3)	23 (32.4)		64 (37.6)	11 (36.7)	
Dose reduction after FN				33/169 (19.5)	19/27 (70.4)	< 0.001
Interim response						
Complete response	83 (64.3)	36 (50.7)	0.032	109 (64.1)	10 (33.3)	0.005
Partial response	41 (31.8)	25 (35.2)		52 (30.6)	14 (46.7)	
Stable disease	1 (0.8)	0 (0)		1 (0.5)	0 (0)	
Progression disease	1 (0.8)	5 (7.0)		3 (1.8)	3 (10.0)	
Unknown	3 (2.3)	5 (7.0)		5 (2.9)	3 (10.0)	
2-Year response (%)						
Progression-free survival	74.7	62.5	0.067	74.0	51.1	0.002
Overall survival	86.4	71.2	0.026	85.0	58.2	0.001

Values are presented as median (range) or number (%) unless otherwise indicated. p-values for continuous variables were calculated with the use of the independent t test, and p-values for categorical variables were calculated with the use of the chi-square test or Fisher exact test. ABC, activated B-cell; B2MG, beta-2 microglobulin; CIN, chemotherapy-induced neutropenia; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; FN, febrile neutropenia; GCB, germinal center B-cell; IPI, International Prognostic Index; LDH, lactate dehydrogenase.